<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01088373</url>
  </required_header>
  <id_info>
    <org_study_id>AZA-REV-09</org_study_id>
    <nct_id>NCT01088373</nct_id>
  </id_info>
  <brief_title>Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q</brief_title>
  <acronym>GFM-AZA-REV-09</acronym>
  <official_title>A Phase II Study of the Efficacy and Safety of Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francophone des Myelodysplasies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francophone des Myelodysplasies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Higher risk MDS with del(5q) carry very poor prognosis, but show some response to azacitidine&#xD;
      and Lenalidomide as single agents . The combination of Lenalidomide and Azacytidine is&#xD;
      currently tested in non del 5q MDS patients. Preliminary results have been recently presented&#xD;
      at ASH meeting (Sekeres et al, 2007).&#xD;
&#xD;
      Overall, the combination of Lenalidomide and Azacitidine is well-tolerated and early results&#xD;
      suggest some efficacy in advanced MDS without del 5q.&#xD;
&#xD;
      In this trial, we will combine Lenalidomide to Azacytidine in higher risk MDS with del (5q).&#xD;
&#xD;
      Patients will receive azacitidine( 75mg/m2/day for 5 days every 28 days) combined to&#xD;
      escalating doses of lenalidomide (starting at relatively low dose).&#xD;
&#xD;
      For patients in hematological CR, PR, HI or marrow CR after cycle 2 or 4, it is mandatory to&#xD;
      continue on Azacitidine + Lenalidomide as long as there is no unacceptable toxicity or overt&#xD;
      progression, with the schedule that yielded response.&#xD;
&#xD;
      In patient still responding after 52 weeks, the drug will continue to be supplied, and follow&#xD;
      up until death will be continued in all patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 25, 2010</start_date>
  <completion_date type="Actual">July 25, 2016</completion_date>
  <primary_completion_date type="Actual">July 25, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To identify the &quot;safe most successful dose&quot;(sMSD) that is the dose level where the probabilities of success is maximized across the dose levels and the toxicity rate is kept within acceptable boundaries.</measure>
    <time_frame>2 and 4 months of treatment</time_frame>
    <description>Briefly, dose limiting toxicity would be defined by having greater than 30% occurrence of unexpected grade III-IV hematological or non hematological toxicity. Efficacy would be defined as a response rate of 40% after 2 cycles. Overall, 49 patients will be included.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate and safety</measure>
    <time_frame>36 months</time_frame>
    <description>response rate (according to IWG 2006 criteria) to the combination of lenalidomide and azacitidine in adult high and int 2 MDS with del 5q&#xD;
safety (particularly hematological toxicity) of the combination of Lenalidomide and azacitidine in int-2 and high risk MDS with del 5q [31].&#xD;
duration of response,&#xD;
progression to AML,&#xD;
and overall survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Azacitidine, Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine combined to Lenalidomide</intervention_name>
    <description>Azacitidine: 75mg/m2/d for 5 days per cycle of 28 days. Lenalidomide: 5mg/day during 14 days for cohort 1. Lenalidomide: 5mg/day during 21 days for cohort 2. Lenalidomide: 10mg/day during 21 days for cohort 3.</description>
    <arm_group_label>Azacitidine, Lenalidomide</arm_group_label>
    <other_name>Vidaza.</other_name>
    <other_name>Revlimid.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age &gt; ou = 18 years and &lt; 75 years.&#xD;
&#xD;
          2. must understand and voluntarily sign an informed consent form.&#xD;
&#xD;
          3. patient considered ineligible for intensive chemotherapy due to age, cardiac&#xD;
             contraindication to anthracyclines, comorbidities, previous failure of intensive&#xD;
             chemotherapy, or patient willing to avoid intensive chemotherapy.&#xD;
&#xD;
          4. must be able to adhere to the study visit schedule and other protocol requirements.&#xD;
&#xD;
          5. prior thalidomide allowed.&#xD;
&#xD;
          6. documented diagnosis of MDS (according to FAB definition, ie. with marrow blasts up to&#xD;
             30%, or CMML with WBC &lt; 13000/mm3 that meets IPSS criteria for intermediate-2 or&#xD;
             high-risk disease.&#xD;
&#xD;
          7. with an associated del 5q[31](the deleted chromosomal region must include 5q[31]),&#xD;
             with or without additional cytogenetic abnormalities.&#xD;
&#xD;
          8. female subjects of childbearing potential must:&#xD;
&#xD;
               -  understand the study drug is expected to have a teratogenic risk.&#xD;
&#xD;
               -  agree to have a medically supervised pregnancy test with a minimum sensitivity of&#xD;
                  25mIU/ml on the day of the study visit or in the 3 days prior to the study visit&#xD;
                  once the subject has been on effective contraception for at least weeks. This&#xD;
                  requirement also applies to women of childbearing potential who practice complete&#xD;
                  and continued abstinence. the test should ensure the subject is not pregnant when&#xD;
                  she starts treatment.&#xD;
&#xD;
               -  agree to have a medically supervised pregnancy test every 4 weeks including 4&#xD;
                  weeks after the end of study treatment, except in the case of confirmed tubal&#xD;
                  sterilization. these pregnancy tests should be performed on the day of the study&#xD;
                  visit or in the 3 days prior to the study visit.&#xD;
&#xD;
             this requirement also applies to women of childbearing potential who practice complete&#xD;
             and continued abstinence.&#xD;
&#xD;
             * agree to use, and to be able to comply with effective contraception without&#xD;
             interruption, 4 weeks before starting study drug throughout the entire duration study&#xD;
             drug therapy(including doses interruptions)and for 3 months after the end of the study&#xD;
             drug therapy even if she has amenorrhea this applies unless the subject commits to&#xD;
             absolute and continuous abstinence confirmed on a monthly basis, to avoid pregnancy&#xD;
             for the duration of study.&#xD;
&#xD;
             the following are effective methods of contraception:&#xD;
&#xD;
               -  implant&#xD;
&#xD;
               -  levonorgestrel-releasing intrauterine system(IUS)&#xD;
&#xD;
               -  Medroxyprogesterone acetate depot, tubal sterilization.&#xD;
&#xD;
               -  sexual intercourse with a vasectomised male partner only(vasectomised must be&#xD;
                  confirmed by two negative semen analyses), ovulation inhibitory progesterone-only&#xD;
                  pills(i.e.desogestrel).&#xD;
&#xD;
             if not established on effective contraception, the female subject must be referred to&#xD;
             an appropriately trained health care professional for contraceptive advice in order&#xD;
             that contraception can be initiated.&#xD;
&#xD;
             Because of the increased risk of venous thromboembolism in patients with multiple&#xD;
             myeloma taking lenalidomide and dexamethasone, combined oral contraceptive pills are&#xD;
             not recommended. If a female subject is currently using combined oral contraception,&#xD;
             the patient should switch to one of the effective methods listed above. The risk of&#xD;
             venous thromboembolism continues for 4 to 6 weeks after discontinuing combined oral&#xD;
             contraception. The efficacy of contraceptive steroids may be reduced during&#xD;
             co-treatment with dexamethasone.&#xD;
&#xD;
             Implants and levonorgestrel-releasing intrauterine systems are associated with an&#xD;
             increased risk of infection at the time of insertion and irregular vaginal bleeding.&#xD;
             Prophylactic antibiotics should be considered particularly in patients with&#xD;
             neutropenia .&#xD;
&#xD;
             Copper-releasing intrauterine devices are generally not recommended due to the&#xD;
             potential risks of infection at the time of insertion and menstrual blood loss which&#xD;
             may compromise patients with neutropenia or thrombocytopenia.&#xD;
&#xD;
               -  Understand that even if she has amenorrhea, she must follow all the advice on&#xD;
                  effective contraception.&#xD;
&#xD;
               -  She understands the potential consequences of pregnancy and the need to rapidly&#xD;
                  consult if there is a risk of pregnancy&#xD;
&#xD;
          9. Male patients must :&#xD;
&#xD;
               -  Agree the need for the use of a condom if engaged in sexual activity with a woman&#xD;
                  of childbearing potential. during the entire period of treatment, even if&#xD;
                  disruption of treatment and during 3 months after end of treatment&#xD;
&#xD;
               -  Agree not to conceive during treatment and study drug therapy (including doses&#xD;
                  interruptions) and for 3 months after the end of the study drug therapy&#xD;
&#xD;
               -  Agree not to donate semen during study drug therapy and for one week after end of&#xD;
                  study drug therapy.&#xD;
&#xD;
               -  Agree to learn about the procedures for preservation of sperm., before starting&#xD;
                  treatment&#xD;
&#xD;
         10. All subjects must :&#xD;
&#xD;
               -  Agree to abstain from donating blood while taking study drug therapy and for one&#xD;
                  week following discontinuation of study drug therapy.&#xD;
&#xD;
               -  Agree not to share study medication with another person and to return all unused&#xD;
                  study drug to the investigator.&#xD;
&#xD;
         11. Signed informed consent prior to start of any study-specific procedures,&#xD;
&#xD;
         12. Ability to participate to a clinical trial and adhere to study procedures.&#xD;
&#xD;
               -  Criteria for women of non-childbearing potential :&#xD;
&#xD;
        A female patient or a female partner of a male patient is considered to have childbearing&#xD;
        potential unless she meets at least one of the following criteria:&#xD;
&#xD;
          -  Age ≥ 50 years and naturally amenorrhoeic for ≥ 1 year (amenorrhoea following cancer&#xD;
             therapy does not rule out childbearing potential)&#xD;
&#xD;
          -  Premature ovarian failure confirmed by a specialist gynaecologist&#xD;
&#xD;
          -  Previous bilateral salpingo-oophorectomy, or hysterectomy&#xD;
&#xD;
          -  XY genotype, Turner syndrome, uterine agenesis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lionel ADES, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>GFM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital kremlin Bicêtre</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <state>IDF</state>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Brabois</name>
      <address>
        <city>Nancy</city>
        <state>Vandoeuvre</state>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>43033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la cote basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Haut-Lévèque</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH René Dubos</name>
      <address>
        <city>Cergy-pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63058</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sud-Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Le mans</name>
      <address>
        <city>Le mans</city>
        <zip>72037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Lens</name>
      <address>
        <city>Lens</city>
        <zip>32307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Heriot, dpt Hématologie Clinique</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmette, Département d'hématologie</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de l'Hotel Dieu, Hematology Dpt</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR La Source orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital la pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cochin Service d'Hématologie</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Maréchal Joffre</name>
      <address>
        <city>Perpignan</city>
        <zip>66046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean-Bernard</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>centre hospitalier Jacques Puel</name>
      <address>
        <city>Rodez</city>
        <zip>12027</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Purpan, médecine Interne</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital PURPAN, Service d'Hématologie Clinique</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gfmgroup.org/</url>
    <description>Website of the Groupe Francophone des Myélodysplasies (GFM)</description>
  </link>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>March 16, 2010</study_first_submitted>
  <study_first_submitted_qc>March 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2010</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

